<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0">
<channel>
<title>Department of Urology Faculty Papers</title>
<copyright>Copyright (c) 2013 Thomas Jefferson University All rights reserved.</copyright>
<link>http://jdc.jefferson.edu/urologyfp</link>
<description>Recent documents in Department of Urology Faculty Papers</description>
<language>en-us</language>
<lastBuildDate>Fri, 22 Feb 2013 17:50:04 PST</lastBuildDate>
<ttl>3600</ttl>








<item>
<title>What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival.</title>
<link>http://jdc.jefferson.edu/urologyfp/17</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/17</guid>
<pubDate>Tue, 27 Mar 2012 11:26:41 PDT</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND AND PURPOSE: For many years, the gold standard in upper urinary tract transitional-cell carcinoma (UT-TCC) management has been nephroureterectomy with excision of the bladder cuff. Advances in endourologic instrumentation have allowed urologists to manage this malignancy. The feasibility and success of conservative measures for UT-TCC have been widely published, but there has not been an objective cost analysis performed to date. Our goal was to examine the direct costs of renal-sparing conservative measures v nephroureterectomy and subsequent chronic kidney disease (CKD) or end-stage renal disease (ESRD). Secondary analysis includes a discussion of survival and quality-of-life issues for both treatment cohorts.</p>
<p>PATIENTS AND METHODS: Retrospective review of a cohort of patients treated at our institution with renal-sparing ureteroscopic management of UT-TCC who were followed for a minimum of 2 years. The costs per case were based on equipment, anesthesia, surgeon fees, pathologic evaluation fees, and hospital stay. ESRD and CKD costs were estimated based on published reports.</p>
<p>RESULTS: From 1996 to 2006, 254 patients were evaluated and treated for UT-TCC at our institution. A cohort of 57 patients was examined who had a minimum follow-up period of 2 years. Renal preservation in our series approached 81%, with cancer-specific survival of 94.7%. Assuming a worst-case scenario of a solitary kidney with recurrences at each follow-up for 5 years v nephroureterectomy and dialysis for the same period, an estimated $252,272 U.S. dollars would be saved. This savings would cover the expenses of five cadaveric renal transplantations.</p>
<p>CONCLUSIONS: Conservative endoscopic management of UT-TCC in our experience should be the gold standard management for low-grade and superficial-stage disease. From a cost perspective, renal-sparing UT-TCC management is effective in reducing ESRD health care expenses.</p>

	]]>
</description>

<author>Raymond W Pak et al.</author>


<category>Aged</category>

<category>Algorithms</category>

<category>Carcinoma, Transitional Cell</category>

<category>Costs and Cost Analysis</category>

<category>Humans</category>

<category>Kidney</category>

<category>Kidney Failure, Chronic</category>

<category>Kidney Neoplasms</category>

<category>Laser Therapy</category>

<category>Survival Analysis</category>

<category>Time Factors</category>

<category>Ureteroscopy</category>

</item>






<item>
<title>Robotic surgery training with commercially available simulation systems in 2011: a current review and practice pattern survey from the society of urologic robotic surgeons.</title>
<link>http://jdc.jefferson.edu/urologyfp/16</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/16</guid>
<pubDate>Thu, 22 Mar 2012 12:43:15 PDT</pubDate>
<description>
	<![CDATA[
	<p>Abstract Objectives: Virtual reality (VR) simulation has the potential to standardize surgical training for robotic surgery. We sought to evaluate all commercially available VR robotic simulators. Materials and Methods: A MEDLINE(®) literature search was performed of all applicable keywords. Available VR simulators were evaluated with regard to face, content, and construct validation. Additionally, a survey was e-mailed to all members of the Endourological Society, querying the pervasiveness of VR simulators in robotic surgical training. Finally, each company was e-mailed to ask for a price quote for their respective system. Results: There are four VR robotic surgical simulators currently available: RoSS™, dV-Trainer™, SEP Robot™, and da Vinci(®) Skills Simulator™. Each system is represented in the literature and all possess varying degrees of face, content, and construct validity. Although all systems have basic skill sets with performance analysis and metrics software, most do not contain procedural components. When evaluating the results of our survey, most respondents did not possess a VR simulator although almost all believed there to be great potential for these devices in robotic surgical training. With the exception of the SEP Robot, all VR simulators are similar in price. Conclusions: VR simulators have a definite role in the future of robotic surgical training. Although the simulators target technical components of training, their largest impact will be appreciated when incorporated into a comprehensive educational curriculum.</p>

	]]>
</description>

<author>Costas D Lallas et al.</author>


</item>






<item>
<title>Urolithiasis location and size and the association with microhematuria and stone-related symptoms.</title>
<link>http://jdc.jefferson.edu/urologyfp/15</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/15</guid>
<pubDate>Fri, 16 Mar 2012 10:57:49 PDT</pubDate>
<description>
	<![CDATA[
	<p>PURPOSE: To conduct a study to assess the association between calculus location and size and the incidence of both microhematuria and symptoms of urolithiasis in a urology office environment.</p>
<p>PATIENTS AND METHODS: After Institutional Review Board approval, a prospective study was conducted with data from 100 consecutive patients who presented to our office with documented urolithiasis. The location (caliceal, pelvic, or ureteral) and size (</p>
<p>RESULTS: A total of 111 stones were found in the study population resulting in a 45.9% incidence of microhematuria. In patients with renal pelvic and ureteral stones, 67.6% demonstrated microhematuria vs 36.4% with caliceal stones, P=0.0035. For stones ≥ 8 mm, 62.5% were positive for microhematuria vs 29.1% of stones <8 >mm, P=0.0006. Ureteral or renal pelvic stones caused the most symptoms (70.6%) compared with caliceal stones (16.9%), P=0.0001. In those patients who reported pain associated with urolithiasis, 65.6% had concomitant microhematuria vs 36.8% in those without pain, P=0.0097.</p>
<p>CONCLUSIONS: Urinary calculus location and size are associated with the incidence of microhematuria and stone-related symptoms. Pain related to urolithiasis may be a positive predictor for the presence of microhematuria.</p>

	]]>
</description>

<author>Costas D Lallas et al.</author>


</item>






<item>
<title>Hand problems among endourologists.</title>
<link>http://jdc.jefferson.edu/urologyfp/14</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/14</guid>
<pubDate>Mon, 23 Jan 2012 11:18:48 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND AND PURPOSE: Endourology has evolved rapidly for the management of both benign and malignant disease of the upper urinary tract. Limited data exist, however, on the occupational hazards posed by complex endourologic procedures. The aim of this study was to determine the prevalence and possible causes of hand problems among endourologists who routinely perform flexible ureteroscopy compared with controls.</p>
<p>MATERIALS AND METHODS: An online computer survey targeted members of the Endourological Society and psychiatrists in academic and community settings. A total of 600 endourologists and 578 psychiatrists were contacted by e-mail. Invited physicians were queried regarding their practice settings and symptoms of hand pain, neuropathy, and/or discomfort.</p>
<p>RESULTS: Survey responses were obtained from 122 (20.3%) endourologists and 74 (12.8%) psychiatrists. Of endourologists, 61% were in an academic setting and 70% devoted their practice to endourology. Endourologists were in practice for a mean 13 years, performing 4.5 ureteroscopic cases per week with a mean operative time of 50 minutes. Hand/wrist problems were reported by 39 (32%) endourologists compared with 14 (19%) psychiatrists (P=0.0486, relative risk [RR]=1.69). Surgeons who preferred counterintuitive ureteroscope deflection were significantly more likely to have problems (56%) compared with intuitive users (27%) (RR 2.07, P=0.0139) or those with no preference (26%) (RR 2.15, P=0.0451). Overall, most respondents (85%) with hand/wrist problems needed either medical or surgical intervention.</p>
<p>CONCLUSIONS: Hand and wrist problems are very common among endourologists. Future studies are needed to develop more ergonomic platforms and thereby reduce the endourologist's exposure to these occupational hazards.</p>

	]]>
</description>

<author>Kelly A Healy et al.</author>


</item>






<item>
<title>Urological involvement in renal transplantation.</title>
<link>http://jdc.jefferson.edu/urologyfp/13</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/13</guid>
<pubDate>Mon, 28 Mar 2011 09:50:29 PDT</pubDate>
<description>
	<![CDATA[
	<p>Historically, urologists were the primary surgeons in renal transplantation. Specialization and increased complexity of the field of transplantation, coupled with a de-emphasis of vascular surgical training in urology, has created a situation where many renal transplants are carried out by surgeons with a general surgery background. Because of its genitourinary nature, however, urological input in renal transplantation is still vital. For living donors, a urologist should be involved to help evaluate and prepare certain patients for eventual donation. This could involve both medical and surgical intervention. Additionally, urologists who carry out living donor nephrectomy maintain a sense of ownership in the renal transplant process and provide a unique opportunity to the trainees of that particular program. For renal transplant recipients, preoperative evaluation of voiding dysfunction and other genitourinary anomalies might be necessary before the transplant. Also, occasional surgical intervention to prepare a patient for renal transplant might be necessary, such as in a patient with a small renal mass that is detected by a screening pretransplant ultrasound. Intraoperatively, for patients with complex urological reconstructions that might be related to the etiology of the renal failure (urinary diversion, bladder augmentation), a urologist who is familiar with the anatomy should be available. Postoperatively, urological evaluation and intervention might be necessary for patients who had a pre-existing urological condition or who might have developed something de novo after the transplant. Although renal transplant programs could consult an on-call urologist for particular issues on an as-needed basis, having a urologist, who has repeated exposure to the particular issues and procedures that are involved with renal transplantation, and who is part of a dedicated multidisciplinary renal transplant team, provides optimal quality of care to these complex patients.</p>

	]]>
</description>

<author>Daniel D Sackett et al.</author>


</item>






<item>
<title>The Minimally Invasive Management of Ureteropelvic Junction Obstruction in Horseshoe Kidneys</title>
<link>http://jdc.jefferson.edu/urologyfp/12</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/12</guid>
<pubDate>Mon, 14 Feb 2011 11:43:52 PST</pubDate>
<description>
	<![CDATA[
	<p>Purpose: Data regarding the treatment of ureteropelvic junction obstruction (UPJO) in horseshoe kidneys are limited. We performed a retrospective analysis of our experience with minimally invasive treatment of UPJO in patients with this anomaly.   Methods: Between March of 1996 and March 2008, 9 patients with horseshoe kidneys were treated for UPJO at our institution. Of these patients, 6 were managed with retrograde endopyelotomy, 2 with laparoscopic pyeloplasty, and one by robotic pyeloplasty. Outcomes of these procedures were retrospectively reviewed.   Results: A total of nine patients were available for analysis. Four of six patients who underwent endopyelotomy had available follow-up, with a mean of 56 months. The success rate for these patients was 75%. Two of three patients (67%) in the laparoscopic/robotic cohort were successfully treated with a mean follow-up of 21 months.   Conclusions: UPJO in horseshoe kidneys can pose a therapeutic dilemma. The minimally invasive treatment of these patients is feasible with good success rates for both endopyelotomy and laparoscopic/robotic pyeloplasty</p>

	]]>
</description>

<author>Costas D. Lallas, M.D., FACS et al.</author>


</item>






<item>
<title>Is there an optimal management for localized prostate cancer?</title>
<link>http://jdc.jefferson.edu/urologyfp/11</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/11</guid>
<pubDate>Thu, 16 Sep 2010 06:39:46 PDT</pubDate>
<description>
	<![CDATA[
	<p>Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localized prostate cancer (CaP). Various treatment options for localized CaP are discussed in this review article including active surveillance, radical prostatectomy, radiation therapy, and cryotherapy. The paucity of high-level evidence adds a considerable amount of controversy when choosing the "optimal" intervention, for both the treating physician and the patient. The long time course of CaP intervention outcomes, combined with continuing modifications in treatments, further complicate the matter. Lacking randomized trials that compare treatment options, this review article attempts to summarize the different treatment options and associated side-effects, including effects on health-related quality of life, from current published literature.</p>

	]]>
</description>

<author>Jaspreet Singh et al.</author>


</item>






<item>
<title>MicroRNA expression profiling of male breast cancer.</title>
<link>http://jdc.jefferson.edu/urologyfp/10</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/10</guid>
<pubDate>Sat, 07 Aug 2010 11:17:32 PDT</pubDate>
<description>
	<![CDATA[
	<p>INTRODUCTION : MicroRNAs (miRNAs) are a class of small noncoding RNAs that control gene expression by targeting mRNAs and triggering either translation repression or RNA degradation. Their aberrant expression may be involved in human diseases, including cancer. To test the hypothesis that there is a specific miRNA expression signature which characterizes male breast cancers, we performed miRNA microarray analysis in a series of male breast cancers and compared them with cases of male gynecomastia and female breast cancers. METHODS : Paraffin blocks were obtained at the Department of Pathology of Thomas Jefferson University from 28 male patients including 23 breast cancers and five cases of male gynecomastia, and from 10 female ductal breast carcinomas. The RNA harvested was hybridized to miRNA microarrays (~1,100 miRNA probes, including 326 human and 249 mouse miRNA genes, spotted in duplicate). To further support the microarray data, an immunohistochemical analysis for two specific miRNA gene targets (HOXD10 and VEGF) was performed in a small series of male breast carcinoma and gynecomastia samples. RESULTS : We identified a male breast cancer miRNA signature composed of a large portion of underexpressed miRNAs. In particular, 17 miRNAs with increased expression and 26 miRNAs with decreased expression were identified in male breast cancer compared with gynecomastia. Among these miRNAs, some had well-characterized cancer development association and some showed a deregulation in cancer specimens similar to the one previously observed in the published signatures of female breast cancer. Comparing male with female breast cancer miRNA expression signatures, 17 significantly deregulated miRNAs were observed (four overexpressed and 13 underexpressed in male breast cancers). The HOXD10 and VEGF gene immunohistochemical expression significantly follows the corresponding miRNA deregulation. CONCLUSIONS : Our results suggest that specific miRNAs may be directly involved in male breast cancer development and that they may represent a novel diagnostic tool in the characterization of specific cancer gene targets.</p>

	]]>
</description>

<author>Matteo Fassan et al.</author>


</item>






<item>
<title>Editorial comment from Dr Lallas to robotic-assisted laparoscopic radical prostatectomy: learning curve of first 100 cases.</title>
<link>http://jdc.jefferson.edu/urologyfp/9</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/9</guid>
<pubDate>Thu, 22 Jul 2010 10:48:46 PDT</pubDate>
<description>
	<![CDATA[
	<p>Editorial comment.</p>

	]]>
</description>

<author>Costas Lallas</author>


</item>






<item>
<title>Is there an optimal management for localized prostate cancer?</title>
<link>http://jdc.jefferson.edu/urologyfp/8</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/8</guid>
<pubDate>Wed, 07 Jul 2010 08:07:42 PDT</pubDate>
<description>
	<![CDATA[
	<p>Widespread screening with prostate-specific antigen (PSA) has led to a significant increase in the detection of early stage, clinically localized prostate cancer (CaP). Various ­treatment options for localized CaP are discussed in this review article including active ­surveillance, radical prostatectomy, radiation therapy, and cyrotherapy. The paucity of high-level evidence adds a considerable amount of controversy when choosing the “optimal” ­intervention, for both the treating physician and the patient. The long time course of CaP intervention outcomes, combined with continuing modifications in treatments, further complicate the ­matter. Lacking randomized trials that compare treatment options, this review article attempts to summarize the different treatment options and associated side-effects, including effects on health-related quality of life, from current published literature.</p>

	]]>
</description>

<author>Jaspreet Singh et al.</author>


</item>






<item>
<title>The quality-of-life impact of prostate cancer treatments.</title>
<link>http://jdc.jefferson.edu/urologyfp/7</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/7</guid>
<pubDate>Mon, 28 Jun 2010 09:08:40 PDT</pubDate>
<description>
	<![CDATA[
	<p>Many options exist for the treatment of localized prostate cancer. In the decision to choose a therapeutic option for localized disease, many variables need to be considered such as tumor characteristics, clinical stage, the patient's overall health and life expectancy, and preferences of both the physician and patient. Another important consideration is the health-related quality of life (HRQOL) implications of a given treatment option. The importance of HRQOL relative to the potential side effects of prostate cancer treatments has grown over the past few years. Although our collective awareness has increased, objective data on HRQOL for prostate cancer treatment are lacking due to a paucity of prospective clinical trial data. This review defines the concept of HRQOL, discusses what is currently known about the impact of various treatments on HRQOL, and summarizes the recent literature in this area relating to the management of localized prostate cancer.</p>

	]]>
</description>

<author>Jaspreet Singh et al.</author>


</item>






<item>
<title>Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.</title>
<link>http://jdc.jefferson.edu/urologyfp/6</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/6</guid>
<pubDate>Sun, 09 May 2010 17:58:24 PDT</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND: Collecting duct carcinoma (CDC) is a rare but very aggressive variant of kidney carcinoma that arises from the epithelium of Bellini's ducts, in the distal portion of the nephron. In order to gain an insight into the biology of this tumor we evaluated the expression of five genes involved in the development of renal cancer (FEZ1/LZTS1, FHIT, TP53, P27kip1, and BCL2). METHODS: We studied eleven patients who underwent radical nephrectomy for primary CDC. All patients had an adequate clinical follow-up and none of them received any systemic therapy before surgery. The expression of the five markers for tumor initiation and/or progression were assessed by immunohistochemistry and correlated to the clinicopathological parameters, and survival by univariate analysis. RESULTS: Results showed that Fez1 protein expression was undetectable or substantially reduced in 7 of the 11 (64%) cases. Fhit protein was absent in three cases (27%). The overexpression of p53 protein was predominantly nuclear and detected in 4 of 11 cases (36%). Immunostaining for p27 was absent in 5 of 11 cases (45.5%). Five of the six remaining cases (90%) showed exclusively cytoplasmic protein expression, where, in the last case, p27 protein was detected in both nucleus and cytoplasm. Bcl2 expression with 100% of the tumor cells positive was observed in 4 of 11 (36%) cases. Statistical analysis showed a statistical trend (P = 0.06) between loss and reduction of Fez1 and presence of lymph node metastases. CONCLUSIONS: These findings suggest that Fez1 may represent not only a molecular diagnostic marker but also a prognostic marker in CDC.</p>

	]]>
</description>

<author>Andrea Vecchione et al.</author>


</item>






<item>
<title>Transperitoneal robotic-assisted laparoscopic prostatectomy after prosthetic mesh herniorrhaphy.</title>
<link>http://jdc.jefferson.edu/urologyfp/5</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/5</guid>
<pubDate>Fri, 13 Nov 2009 10:31:09 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND AND OBJECTIVES: We report our institutional experience performing transperitoneal robotic-assisted laparoscopic prostatectomy (RALP) in patients with prior prosthetic mesh herniorrhaphy to assess the feasibility of this procedure in this patient population. METHODS: From October 2005 to January 2008, transperitoneal robotic-assisted laparoscopic prostatectomies were performed and prospectively recorded. We retrospectively reviewed 309 patients. RESULTS: Twenty-seven patients (8.7%) were found to have a history of prior hernia repair with prosthetic mesh placement. The mean age was 55.7, estimated blood loss (EBL) was 228 mL, operative (console) time was 197 minutes, and length of hospital stay (LOS) was 1.62 days. In contrast, patients undergoing RALP with no history of mesh herniorrhaphy had a mean age of 59.3, EBL of 302 mL, console time of 193 minutes, and LOS of 2.2 days. These differences were not statistically significant. The mesh herniorrhaphy cohort had a lower percentage of organ-confined disease, but no difference was seen in margin status, continence, or potency rates after one year. CONCLUSIONS: Transperitoneal RALP is a feasible option for previously operated on patients with prosthetic mesh herniorrhaphy. Two areas that we identified as critical were the initial step of gaining access for pneumoperitoneum and port placement, and meticulous dissection to expose the mesh, which can be subsequently avoided and left intact. As RALP continues to gain popularity, urologists will continue to exploit the advantages of robotic surgery to perform increasingly challenging cases.</p>

	]]>
</description>

<author>Costas D. Lallas et al.</author>


</item>






<item>
<title>Robotic dismembered pyeloplasty in a horseshoe kidney after failed endopyelotomy.</title>
<link>http://jdc.jefferson.edu/urologyfp/4</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/4</guid>
<pubDate>Fri, 13 Nov 2009 10:21:13 PST</pubDate>
<description>
	<![CDATA[
	<p>We report our experience performing a robot-assisted dismembered pyeloplasty on a patient with a ureteropelvic junction obstruction in a horseshoe kidney and a prior history of endopyelotomy. We provide 18-month follow-up demonstrating that robotic pyeloplasty is a reasonable second treatment option for patients with horseshoe kidneys with failed prior endourological management.</p>

	]]>
</description>

<author>Mark L. Pe et al.</author>


</item>






<item>
<title>Rhabdomyolysis after laparoscopic nephrectomy.</title>
<link>http://jdc.jefferson.edu/urologyfp/3</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/3</guid>
<pubDate>Fri, 13 Nov 2009 10:13:16 PST</pubDate>
<description>
	<![CDATA[
	<p>BACKGROUND AND OBJECTIVES: Laparoscopic renal surgery has become a widely applied technique in recent years. The development of postoperative rhabdomyolysis is a known but rare complication of laparoscopic renal surgery. Herein, 4 cases of rhabdomyolysis and a review of the literature are presented with respect to pathogenesis, treatment, and prevention of this dire complication. METHODS: A retrospective review of over 600 laparoscopic renal operations over the past 8 years was performed. All cases of postoperative rhabdomyolysis were identified. A Medline search was performed to find articles related to the development of postoperative rhabdomyolysis. Cases of rhabdomyolysis developing after laparoscopic renal surgery and common risk factors between cases were identified. RESULTS: The incidence of postoperative rhabdomyolysis in our series is 0.67%. It is similar to the rate reported in other series. Male sex, high body mass index, prolonged operative times, and the lateral decubitus position are all risk factors in its development. CONCLUSION: The prevention and optimal management of postoperative rhabdomyolysis following laparoscopic renal surgery has yet to be defined. The risk factors we identified should be carefully addressed and minimized. A better understanding of the pathogenesis of rhabdomyolysis will also be a key component in its prevention.</p>

	]]>
</description>

<author>Deborah T. Glassman et al.</author>


</item>






<item>
<title>The minimally invasive treatment of ureteropelvic junction obstruction: a review of our experience during the last decade.</title>
<link>http://jdc.jefferson.edu/urologyfp/2</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/2</guid>
<pubDate>Tue, 28 Oct 2008 14:41:37 PDT</pubDate>
<description>
	<![CDATA[
	<p><strong>PURPOSE</strong>: The minimally invasive treatment of ureteropelvic junction obstruction has evolved during the last decade from endoscopic to laparoscopic and robotic. We review our 10-year experience with ureteropelvic junction obstruction, and report on our experience and followup.</p>
<p><strong>MATERIALS AND METHODS</strong>: We reviewed all patients treated during the last 10 years. There were 294 procedures performed with complete records on 273 patients including 128 retrograde endopyelotomies, 116 laparoscopic pyeloplasties and 29 robotic pyeloplasties. Technique for each procedure is reviewed. Statistical analysis was performed on all results. Variables evaluated were gender, age (younger than 41 vs 41 years or older), side (right or left), presence of crossing vessels, presence of a high insertion, primary or secondary procedure and whether prior endopyelotomy or pyeloplasty had been performed.</p>
<p><strong>RESULTS</strong>: Mean followup for endopyelotomy, laparoscopic pyeloplasty and robotic pyeloplasty was 20, 20 and 19 months, respectively, with success rates of 60.2%, 88.8% and 100%, respectively. On univariable analysis only the presence of crossing vessels or a high insertion was significant for laparoscopic pyeloplasty. On multivariable analysis age was significant for endopyelotomy and the presence of crossing vessels was significant for pyeloplasty. On Kaplan-Meier analysis failures were noted to occur after 5 years in both groups.</p>
<p><strong>CONCLUSIONS</strong>: Laparoscopic pyeloplasty and robotic pyeloplasty are superior minimally invasive treatments for ureteropelvic junction obstruction. However, endopyelotomy can be used for select patients. Because of late failures patients who undergo either of these procedures should receive long-term followup.</p>

	]]>
</description>

<author>Brent V. Yanke et al.</author>


</item>






<item>
<title>Surgical management of metastatic disease to the adrenal gland</title>
<link>http://jdc.jefferson.edu/urologyfp/1</link>
<guid isPermaLink="true">http://jdc.jefferson.edu/urologyfp/1</guid>
<pubDate>Wed, 04 Jun 2008 08:06:16 PDT</pubDate>
<description>
	<![CDATA[
	<p>Metastatic disease to the adrenal glands can occur in a wide array of malignancies. With the increased use of abdominal imaging, these lesions are diagnosed with more frequency. Diagnostic and laboratory evaluation is essential for the differentiation of benign lesions from primary malignant adrenal tumors or extra-adrenal metastasis. Computed tomography (CT) and magnetic resonance imaging (MRI) characteristics, as well as the adjunctive use of immunocytochemical techniques on biopsy specimens, can allow accurate identification of metastatic lesions. Surgical management of metastastic lesions is appropriate in selected patients, primarily when representing the solitary site of metastatic disease. The surgical approach, while debatable, can de done either through open surgery or laparoscopically. Either approach appears comparable in terms of oncologic efficacy in the carefully selected patient, although laparoscopic adrenalectomy is associated with decreased pain and improved convalescence. The surgeon’s skill in laparoscopic technique, appropriate patient selection, and the ability to adhere to oncologic principles, including complete excision without tumor spillage, are of utmost importance when deciding the appropriate surgical intervention.</p>

	]]>
</description>

<author>Paul R. Gittens Jr. et al.</author>


</item>





</channel>
</rss>
